SPRY4 and melanoma: Expression levels of this lncRNA have been evaluated in plasma of melanoma patients and matched controls, showing that patients have higher levels of SPRY4‐IT1 compared with healthy controls, associated with tumor site, tumor stage and poor prognosis (Liu et al., 2016).